Positive primary endpoint data from Novartis’ pivotal Phase III NATALEE trial has been presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Data showed that Kisqali (ribociclib) plus endocrine therapy (ET), compared to ET alone, lowered the risk of cancer recurrence by 25.2%… Read More
Janssen has presented new data from across its oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Talquetamab Talquetamab is an investigational GPRC5D-directed bispecific antibody currently in clinical development. Updated results from the Phase II MonumenTAL-1 study show that… Read More
DDW’s Diana Spencer chats to Macomics’ co-founder and VP Immunology Dr Luca Cassetta about the company’s approach to tumour suppression and the challenges of launching a new business in early 2020. DS: Congratulations on the publication of your discoveries in Nature Reviews Cancer. Your studies focus on tumour associated macrophages (TAMs). What role do they… Read More
A targeted drug combination for patients with a type of ovarian cancer could be nearly twice as effective as the next best treatment, according to interim results from a Phase II study. Researchers hope these results, which were presented at the 2023 American Society of Clinical… Read More
Positive results from the ADAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to placebo. The trial assessed osimertinib as an adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor… Read More
Biopharmaceutical company Syros Pharmaceuticals has announced new clinical data from the Phase I/Ib clinical trial evaluating SY-5609 in patients with relapsed/refractory pancreatic ductal adenocarcinoma (PDAC), HR+ breast cancer and other solid tumours. The data will be presented in two posters at the 2023 American Society for… Read More
Immuno-oncology company Aulos Bioscience has revealed interim results from an ongoing Phase I/II trial of monoclonal antibody AU-007 in solid tumours. The data indicate that AU-007 is well tolerated in patients with unresectable locally advanced or metastatic cancer and there are early signs of anti-tumour activity. Read More
From antibody-drug conjugates and RNA, to CRISPR and CAR-T therapy, DDW asked the drug discovery industry what the most important development in oncology over the last five years has been. As the US National Cancer Research Month draws to a close, we asked experts from across the industry “What do… Read More
Pancreatic cancer cells can change their ‘diet’ to keep growing, by switching from the sugar glucose to a back-up fuel called uridine, new research has revealed. The findings suggest that blocking the availability of uridine using new drugs could become a new treatment strategy for the… Read More
Scientists in Japan have used a novel technique to identify a protein complex degraded by autophagy that has a possible role in liver cancer. Biomolecular condensates like p62 body have a role in cleansing cellular waste through ‘autophagy’, though much remains unknown about the constituents of… Read More
Bayer and Bicycle Therapeutics have entered into a strategic collaboration agreement to discover, develop, manufacture, and commercialise Bicycle radioconjugates for multiple oncology targets. Bicyclic peptides are peptides consisting of 9-20 amino acids that can be synthetically manufactured and bind to targets with high affinity and selectivity,… Read More
An ovarian cancer drug, which targets the alpha folate receptor (FRα), is set to enter Phase II trials. Idetrexed (formerly known as BTG945, ONX-0901 and CT900) was created by scientific teams in what is now The Institute of Cancer Research (ICR) Centre for Cancer Drug Discovery,… Read More
Jantzen Sperry, PhD, Director of Scientific Operations at Certis Oncology looks at how the adoption of orthotopic PDX models can elevate the impact of cancer research and improve translation in oncology drug development. The recent passage of the FDA Modernization Act, which removed the requirement for animal testing when suitable… Read More
Listen to this article on the DDW Podcast: Anthony Schmitt, PhD, Senior Vice President, Science at Arima Genomics, discusses the applications of 3D genomics in cancer research. Efforts to fulfil the promise of precision medicine, including the use of targeted cancer therapies, necessitate that patients be treated based on the specific genetic… Read More
New research in mice has identified how gut bacteria alter the body’s response to PD-1 checkpoint blockade immunotherapy, currently used for the treatment of 25 forms of cancer. The findings could inform the design of treatments that boost the efficacy of cancer immunotherapy among patients with… Read More
New research indicates that for patients with advanced skin cancer, it may be important to maintain normal vitamin D levels when receiving treatment with immune checkpoint inhibitors. The findings are published in CANCER, a peer-reviewed journal of the American Cancer Society. Vitamin D has… Read More
